GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

计划入组 36 人 · 首次发布于 2020 年 10 月 26 日

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

计划入组 131 人 · 首次发布于 2017 年 8 月 15 日

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

计划入组 17 人 · 首次发布于 2020 年 8 月 24 日

Inotuzumab Ozogamicin(Besponsa)

Rx

Blinatumomab(Blincyto)

Rx

Precursor

AB&B BIO-TECH-B

Gamida Cell

Israel

GAMIDA CELL INC.

United States

FDA Approves Obecabtagene Autoleucel (Obe-cel) for Relapsed/Refractory B-Cell Precursor ALL

FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL

Real-World Study Confirms Blinatumomab Effectiveness as Bridge to Transplant in B-Cell Precursor ALL